⚠ COVID-19 INFORMATION: Resources, Vaccine Information

Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)

Official Title: Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)

There are 2 panels in this study. In Panel A, POS IV will be evaluated in ≥8 participants, including ≥5 who are <3 months of age and ≥3 who are 3 months to <2 years of age. In Panel B, both POS IV and POS PFS will be evaluated in ≥14 participants, including ≥3 who are <3 months of age and ≥5 who transition to the PFS formulation of POS.

NCT04665037
Muller, William J., MD, PhD
Interventional
Yes

Contact Information:

Laura Fearn

312.227.6285